Document is current
Any future updates will be listed below
-
Authors
Carugo, Stefano
Vescini, Fabio
Giusti, Andrea
Mauro, Giulia Letizia
Tafaro, Laura
Festuccia, Francescaromana
Muraca, Lucia
Menè, Paolo
Rossini, Maurizio https://orcid.org/0000-0001-9692-2293
-
Funding
Funding for this research was provided by:
Italfarmaco
- License Information
-
More Information
Article History
Received: 31 May 2024
Accepted: 23 September 2024
First Online: 22 October 2024
Declarations
:
: M.R.: advisory board honoraria, consultancy fees, and/or speaker fees from AbbVie, Eli-Lilly, Galapagos, ItalFarmaco, Neopharmed Gentili, Theramex, and UCB Pharma. F.V.: received consulting fees from Abiogen Pharma, Bruno farmaceutici, Italfarmaco, UCB Pharma, AMGEN, IBSA, and Theramex. A.G.: received consulting fees from Abiogen Pharma, Italfarmaco, UCB Pharma, AMGEN, IBSA and Kyowa Kirin. S.C., G.L.M., L.T., F.F., L.M., and P.M.: None.
